Alzheimer's disease: Clinical trials to watch
- PMID: 40782673
- DOI: 10.1016/j.medj.2025.100771
Alzheimer's disease: Clinical trials to watch
Abstract
Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events. Here we highlight several ongoing clinical trials, aiming to develop therapeutic agents with higher efficacy and better safety profiles including third-generation ATTs, aggregation inhibitors, Sigma-1 receptor agonists, anti-tau antisense oligonucleotides, and GLP-1 receptor agonists.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Dr. Sabbagh discloses that he consults for Alzheon, Athira, Roche-Genentech, Synaptogenix, Novo Nordisk, Signant Health, Eisai, GSK, Abbvie, Lilly, and Neurotherapia. Dr. Decourt is a consultant to Lighthouse Therapeutics. Jessica Kennedy and Jad Majeed have no disclosures to report.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
